Elamipretide, SS-31 and Forzinity: what the FDA approval covers

The question

Forzinity, the prescription elamipretide injection, received US accelerated approval on September 19, 2025 to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. That is a specific medical indication. It is not an approval of SS-31 research vials for general energy, anti-aging or athletic performance. FDA approval announcement.

The interesting part of this research story is not simply that a peptide reached approval. It is how a small rare-disease study, an intermediate endpoint and a required confirmatory trial fit together.

Start with the names

Elamipretide was developed under names including SS-31. Sponsor materials submitted for an FDA advisory meeting describe it as a mitochondrial-targeted tetrapeptide interacting with cardiolipin. This identifies the compound and its research rationale; sponsor descriptions of a mechanism are not, by themselves, proof of a clinical benefit. Sponsor briefing document hosted by FDA.

Forzinity is the approved finished medicine. SS-31 is also a name used in research catalogs. Treating those names as fully interchangeable skips the product question: which formulation was manufactured, reviewed and studied?

A hypothetical seller could use the same compound name on a label without thereby acquiring the medicine's approval. Readers should check the finished product, indication and population rather than using a molecule's name as a universal regulatory stamp.

What happened in the randomized study

The TAZPOWER program included a randomized, blinded crossover study and an open-label extension. In a crossover design, participants receive both study treatments in different periods, with the order assigned at random. The original report describes elamipretide and placebo periods separated by a washout. Original trial publication.

FDA's trial snapshot describes 12 participants with Barth syndrome at a single US site. It distinguishes the initial randomized comparison from the longer period in which participants received active treatment openly. Improvement in knee-extensor strength was observed during the longer open-label period; a significant difference was not shown during the initial randomized portion. FDA trial snapshot.

That design change affects interpretation. During an open-label extension, improvement is measured without the same concurrent randomized placebo comparison. Time, repeated testing and which participants remain in follow-up can complicate attribution. Those limitations do not make the observations worthless, but they prevent the extension from being described as if it supplied the same comparison as the blinded phase.

Why approval and further confirmation can coexist

The prescribing information states that Forzinity was not superior to placebo on the randomized study's primary walking-distance and fatigue endpoints. Its indication was approved under the accelerated pathway based on knee-extensor strength, an intermediate clinical endpoint. Continued approval may depend on confirming clinical benefit. Forzinity prescribing information.

FDA explained that the strength finding was considered reasonably likely to predict patient benefit and required a further randomized, blinded, placebo-controlled trial. FDA's explanation of the decision.

Two misleading summaries are easy to write here. “The trial proved every intended benefit” overstates the initial evidence. “Further research is needed, so the product is unapproved” misstates the regulatory decision. A more useful account preserves both facts: approval exists for a defined use, and an important confirmation obligation remains.

The next trial is designed around function

The official 4TAZPower record, checked October 4, 2026, lists the confirmatory study as recruiting. It reports an actual start date of July 2, 2026 and an estimated enrollment of 48. Its primary endpoint combines three functional tests over 72 weeks: a six-minute walk, a timed up-and-go test and repeated sit-to-stand performance. The registry's primary completion date is estimated for September 2029. These are study plans and status information, not completed results. 4TAZPower, NCT07531251.

This makes the next question concrete. Does the treatment produce a benefit in the functional measures that the new randomized comparison is designed to evaluate? A recruiting label cannot answer that question. Neither can an estimated completion date be treated as a promised approval milestone.

When results arrive, the useful comparison will include the prespecified combined score, its individual tests, missing data and adverse events. Highlighting only the most favorable test would give an incomplete account of what the trial set out to establish.

A rare-disease result does not establish a longevity benefit

The population is central to this story. People living with Barth syndrome are not a stand-in for healthy adults looking to improve energy or extend life. An approval directed at muscle strength in this disease does not supply an unmeasured lifespan outcome in another population.

The same boundary applies across different mitochondrial peptides. Our MOTS-c human-research article examines a separate compound and question. Sharing a broad cellular research theme does not make the interventions interchangeable.

Safety also remains part of the picture. Forzinity's label includes injection-site reactions and a warning about serious hypersensitivity reactions. These statements concern the reviewed medicine; the label cannot establish the safety of a catalog vial with unknown equivalence. FDA prescribing information. Our peptide COA guide explains why a material test certificate answers another, narrower set of questions.